Here, we set out to generate an isogenic EML4-ALK fusion NSCLC model in the A549 lung cancer cell line (ATCC ® CCL-185IG™), which contains other naturally occurring genomic aberrations inherent ...
EGFR inhibitors are efficacious as second-line or third-line treatment for advanced non-small-cell lung cancer (NSCLC). Treatment with these inhibitors is particularly favorable in women ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback